Terumo Corporation

14 days ago · seekingalpha.com

Terumo Corporation (TRUMY) Discusses Technological Capabilities and R&D Strategy for Sustained Competitive Advantage Transcript

19 days ago · zacks.com

Terumo (TRUMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 months ago · seekingalpha.com

Terumo Corporation (TRUMY) Q1 2027 Earnings Call Prepared Remarks Transcript

3 months ago · zacks.com

Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.

1 year ago · globenewswire.com

New agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreement Terumo to pay a total of $30 million to Orchestra BioMed Orchestra BioMed retains all development and distribution rights to Virtue SAB in all indications Orchestra BioMed recently initiated patient enrollment for the Virtue Trial, its U.S. pivotal IDE trial of Virtue SAB in the treatment of coronary in-stent restenosis (“ISR”) NEW HOPE, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that it has entered into a termination and right of first refusal agreement (the “ROFR Agreement”) with Terumo Corporation (TYO:4543) and Terumo Medical Corporation (collectively, “Terumo”) with respect to Virtue® Sirolimus AngioInfusion™ Balloon (“SAB”) for the treatment of coronary artery disease worldwide.